+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 20Years +
All Genders
ID07014371

Comparing Alternate-Day and Once-Daily Oral Ferrous Fumarate for Treating Iron Deficiency Anemia A Randomized Open-Label Trial

Led by Phramongkutklao College of Medicine and Hospital · Updated on 2026-10-14

60

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are comparing two oral iron supplement schedules for adults with iron deficiency anemia IDA to see if taking iron on alternate days is as effective and better tolerated than taking it once daily. This open-label, randomized clinical trial aims to assess the improvement in hemoglobin levels and side effects of these dosing methods over 8 weeks. Participants are randomly assigned to receive ferrous fumarate 200 mg once daily or 400 mg on alternate days for 8 weeks. Blood tests and clinical assessments will be performed at the start, Week 4, and Week 8 to monitor blood counts, iron levels, and any side effects. Medication adherence is tracked by counting remaining pills. During the study, participants report side effects and attend scheduled visits for evaluations. Researchers measure hemoglobin changes primarily at Week 8, with additional analysis of reticulocyte count and serum ferritin at Weeks 4 and 8. Safety monitoring occurs throughout the 8-week treatment, and the trial concludes at the end of the primary outcome assessment period.

CONDITIONS

Brief Title

Alternate-Day vs. Once-Daily Oral Iron Supplementation in Iron Deficiency Anemia (IDA)

Research Team

T

Tanapun Thamgrang, Doctor of Medicine

A

Aticha Kraiput, Doctor of Medicine

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here